All told, Boston Scientific (NYSE: BSX )
did alright in the second quarter, but the inter-segment noise
highlights one of the ongoing challenges for the company – keeping all
the ducks in a row and delivering both top-line growth and margin
improvement. I'm still skeptical that these shares really make sense
from a long-term cash flow perspective, but I cannot argue that the
company has not made progress and could generate significant earnings
growth in the coming years.
Continue reading here:
Boston Scientific Stock Down Slightly on Earnings
No comments:
Post a Comment